Mission magazine banner
passengers inside airplane

Thousands of men could avoid cancer diagnosis

January 2014

by Elizabeth Allen

The American Society of Clinical Oncology has designated a Health Science Center researcherís work as among the most significant practice-changing studies of 2013.

The long-term follow-up to a groundbreaking finasteride study of 19,000 men, both of which were led by Cancer Therapy & Research Center Director Ian M. Thompson Jr., M.D., confirms that a drug developed for hair growth has no impact on lifespan but reduces the risk of prostate cancer by more than a third.
Dr. Ian Thompson
Ian M. Thompson Jr., M.D.

Reducing the risk of prostate tumors by about 30 percent - and low-grade tumors by 43 percent - means thousands of men can avoid a cancer diagnosis and subsequent treatments that significantly affect quality of life, Dr. Thompson said.

"If you look at the number of prostate cancers that are diagnosed annually and multiply that by 30 percent, thatís the number of cancers we might be able to prevent each year," he said.

"Thatís more than 71,000 men. Thatís more than 175 jumbo jets full of men who wonít get cancer, who wonít face treatments with side effects like sexual dysfunction," Dr. Thompson said.

"Thereís nothing like disease prevention. Nothing comes close," he added.

The Prostate Cancer Prevention Trial, funded by a National Cancer Institute grant, began in 1993. It was coordinated by SWOG, an international network of research institutions. Researchers were at first concerned that it increased some deadlier prostate cancers.

Prostate Cancer Risk Calculator
The Prostate Cancer Risk Calculator, available on the Health Science Center website, has a new, improved 2.0 version free for men and their doctors to use. In moments, a man 55 or older can obtain a trustworthy, science-based risk estimate - information that can help him know what to discuss with his physician.

Click to check your risk assessment.
The follow-up study, published in the New England Journal of Medicine, showed that finasteride did not increase mortality rates, and it decreased low-grade prostate cancer even more than originally thought. It was chosen for ASCOís Clinical Cancer Advances 2013: ASCOís Annual Report on Progress Against Cancer, an independent annual review of the advances in clinical cancer research that have the greatest potential to improve patientsí survival and quality of life.

In todayís medical climate, many men with low-grade tumors are unnecessarily treated, Dr. Thompson noted, and those treatments carry a considerable burden for the patient and for society.

"If we can free thousands of men each year from that burden," he said, "we could use those resources for other important medical interventions, reducing death and suffering from disease."



Home

Subscribe

Previous Issues

Current Issue (PDF)

Flipbook

Email us

HSC News

Make a Gift

University Home

UT Health Science Center
7703 Floyd Curl Dr.
San Antonio, Texas
78229-3900

© 2002 - 2014 UTHSCSA
Office of Communications
All rights reserved.

Links provided from UTHSCSA pages to other websites do not constitute or imply an endorsement of those sites, their content, or products and services associated with those sites.

Updated 7/30/14